Protox lines up $35M for BPH program

Warburg Pincus will invest up to $35 million in Canada's Protox Therapeutics, fueling its new therapy for benign prostatic hyperplasia as it advances into late-stage trials. The investment group will take a 21 percent stake in Protox in exchange for the first $10 million tranche. The additional money is scheduled to arrive in the next year. Story

Suggested Articles

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.